NEC presents Phase I/II results for individualised oral neoantigen therapy
NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).
The findings were presented in an e-poster at the ESMO Congress in Madrid, Spain, from 23-27 October 2026.
NECVAX-NEO1 is an AI powered individualised bacteria-based oral DNA therapy that combines IMMUNASIGHT, NEC Bio’s proprietary AI based neoantigen prediction platform for identifying the most immunogenic patient-specific neoepitopes, with TORAPRIME, its proprietary oral bacterial neoantigen delivery platform.
The therapy is designed to activate a patient’s immune system, prompting a T-cell response that can precisely target and eliminate tumour cells based on an individual’s unique neoantigens.
In the first cohort of the Phase I/II study, eight patients with TNBC were treated with NECVAX-NEO1 in a neoadjuvant setting. All patients were treated with two courses of neoadjuvant chemotherapy and pembrolizumab before the planned surgery. After 12 weeks of chemotherapy/pembrolizumab, NECVAX-NEO1 was added on top, with an optional adjuvant treatment phase after surgery.
NECVAX-NEO1 on top of chemotherapy/immunotherapy was generally well tolerated. Five patients achieved pathological complete response at surgery, accompanied by corresponding biomarker changes. In all patients, immunogenic neoepitopes used in NECVAX-NEO1 were detected, as demonstrated by ELISPOT analysis.
Dr Heinz Lubenau, CEO of NEC Bio Therapeutics, commented: “Our clinical Phase I/II data are demonstrating promising immune responses in the neoadjuvant treatment of early-stage TNBC patients. The results are encouraging, so we are extending the trial to n=28 patients, including patients in the US, as we recently received IND approval to conduct a clinical trial in the country. The additional patients in cohort 2 are being treated with a higher dose of NECVAX-NEO1 on top of Keynote-522 standard of care regimen, which includes pembrolizumab.”
